Again, by way of background, this amendment was reached after taking into consideration the generics' perspective and balancing it in consultation with the innovative medicines, and to deal with the retroactivity, of course, in clause 59. Again, we think we've reached what is.... We know that it's an acceptable compromise to the stakeholders, and we hope it will be acceptable to the committee as well.
On December 14th, 2016. See this statement in context.